The latest news in Fibrous Dysplasia/McCune-Albright Syndrome
The US Department of Defense has just released a funding announcement for the Peer Reviewed Medical Research Program. Fibrous dysplasia was recently named as one of the disease topic areas eligible for funding through the Peer-Reviewed Medical Research Program (PRMRP).Our goal is that FD/MAS researchers are awarded some of the $360 million dollars allocated to the PRMRP, and we hope that many of you will apply.
A description of the program and the four funding mechanisms currently announced can be found here. We anticipate a fifth funding mechanism for Clinical Trials to be released as well. Below is a breakdown of the four available funding mechanisms, as well as their preapplication, and application due dates. Please let us know if you plan to submit a proposal this year.
Discovery Award LOI: April 16th,2020

Application: April 30th, 2020
Focused Program Award Preproposal: April 23rd, 2020 Application: August 6th, 2020
Ivestigator-Initiated Research Award Preproposal: April 23rd, 2020 Application: August 20th, 2020
Technology/Therapeutic Development Preproposal: April 23rd, 2020 Application: August 20th, 2020
Please share this email with any of your colleagues who may be interested in submitting a research proposal that addresses aspects of fibrous dysplasia/McCune-Albright Syndrome  (FD/MAS) and helps support the PRMRP goal of enhancing the health and well-being of military service members, veterans, and their families.

The mutation that causes FD/MAS is located in a very important gene ( GNAS ) that is necessary for the maintenance of healthy bone. For that reason, the study of FD/MAS has a track record of yielding broad insights about bone biology, including the discovery that bone is the body's source of a key kidney-regulating hormone, FGF23. FD/MAS provides a unique natural experiment to study key signaling pathways that have implications for treatments of conditions important to the DOD, including blast-induced heterotopic ossification, chronic bone pain, skeletal fractures, osteoporosis, and osteoarthritis. 

We would also like to share a webinar series about funding and strategies for success: We hope many of you will submit an application. If you have any questions, contact me at
Best regards,
Adrienne McBride
Executive Director
Fibrous Dysplasia Foundation
Fibrous Dysplasia Foundation | |